EFFECTS OF SCH-34826, AN ORALLY ACTIVE INHIBITOR OF ATRIAL-NATRIURETIC-PEPTIDE DEGRADATION, IN HEALTHY-VOLUNTEERS

被引:33
作者
BURNIER, M
GANSLMAYER, M
PERRET, F
PORCHET, M
KOSOGLOU, T
GOULD, A
NUSSBERGER, J
WAEBER, B
BRUNNER, HR
机构
[1] UNIV HOSP, DIV HYPERTENS, LAUSANNE, SWITZERLAND
[2] SCHERING PLOUGH CORP, KENILWORTH, NJ USA
关键词
D O I
10.1038/clpt.1991.123
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atrial natriuretic peptide is cleared from plasma by clearance receptors and by enzymatic degradation by way of a neutral metalloendopeptidase. Inhibition of neutral metalloendopeptidase activity appears to provide an interesting approach to interfere with metabolism of atrial natriuretic peptide to enhance the renal and haemodynamic effects of endogenous atrial natriuretic peptide. In this study, the effects of SCH 34826, a new orally active neutral metalloendopeptidase inhibitor, have been evaluated in a single-blind, placebo-controlled study involving eight healthy volunteers who had maintained a high sodium intake for 5 days. SCH 34826 had no effect on blood pressure or heart rate in these normotensive subjects. SCH 34826 promoted significant increases in excretion of urinary sodium, phosphate, and calcium. The cumulative 5-hour urinary sodium excretion was 15.7 +/- 7.3 mmol for the placebo and 22.9 +/- 5, 26.7 +/- 6 (p < 0.05), and 30.9 +/- 6.8 mmol (p < 0.01) for the 400, 800, and 1600 mg SCH 34826 doses, respectively. During the same time interval, the cumulative urinary phosphate excretion increased by 0.3 +/- 0.4 mmol after placebo and by 1.5 +/- 0.3 (p < 0.01), 1.95 +/- 0.3 (p < 0.01), and 2.4 +/- 0.4 mmol (p < 0.001) after 400, 800, and 1600 mg SCH 34826, respectively. There was no change in diuresis or excretion of urinary potassium and uric acid. The natriuretic response to SCH 34826 occurred in the absence of any change in plasma atrial natriuretic peptide levels but was associated with a dose-dependent elevation of urinary atrial natriuretic peptide and cyclic guanosine monophosphate. These results demonstrate that neutral metalloendopeptidase inhibition with SCH 34826 can produce natriuresis and phosphate excretion in volunteers receiving a high-salt diet maybe by reducing the renal atrial natriuretic peptide metabolism.
引用
收藏
页码:181 / 191
页数:11
相关论文
共 37 条
  • [31] ATRIAL NATRIURETIC HORMONE-SECRETION IN PATIENTS WITH RENAL-FAILURE
    SHENKER, Y
    PORT, FK
    SWARTZ, RD
    GROSS, MD
    GREKIN, RJ
    [J]. LIFE SCIENCES, 1987, 41 (13) : 1635 - 1644
  • [32] INTRARENAL LOCALIZATION OF DEGRADATION OF ATRIAL NATRIURETIC PEPTIDE IN ISOLATED GLOMERULI AND CORTICAL NEPHRON SEGMENTS
    SHIMA, M
    SEINO, Y
    TORIKAI, S
    IMAI, M
    [J]. LIFE SCIENCES, 1988, 43 (04) : 357 - 363
  • [33] SYBERTZ EJ, 1989, J PHARMACOL EXP THER, V250, P624
  • [34] ATRIAL NATRIURETIC FACTOR POTENTIATING AND ANTIHYPERTENSIVE ACTIVITY OF SCH-34826 - AN ORALLY ACTIVE NEUTRAL METALLOENDOPEPTIDASE INHIBITOR
    SYBERTZ, EJ
    CHIU, PJS
    VEMULAPALLI, S
    WATKINS, R
    HASLANGER, MF
    [J]. HYPERTENSION, 1990, 15 (02) : 152 - 161
  • [35] TIKKANEN I, 1985, LANCET, V2, P40
  • [36] TIKKANEN I, 1985, LANCET, V2, P66
  • [37] WEIDMANN P, 1986, J HYPERTENS, V4, pS71